Prenzel Klaus L, König Alexandra, Schneider Paul M, Schnickmann Christian, Baldus Stephan E, Schröder Wolfgang, Bollschweiler Elfriede, Dienes Hans P, Mueller Rolf P, Izbicki Jakob R, Hölscher Arnulf H
Department of Visceral and Vascular Surgery, University of Cologne, Cologne, Germany.
Ann Surg Oncol. 2007 Feb;14(2):954-9. doi: 10.1245/s10434-006-9141-6. Epub 2006 Nov 11.
Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer. The influence on nodal micrometastasis has not yet been evaluated.
This study includes 52 patients with localized (cT2-4, Nx, M0) esophageal cancers (21 adenocarcinomas, 31 squamous cell cancers) who received neoadjuvant chemoradiation (36Gy, 5-FU, cisplatin) followed by transthoracic en bloc esophagectomy with two field lymphadenectomy. The extent of histomorphologic regression was categorized into major (< 10%) and minor response (>10% vital residual tumor cells) as recently reported. A total of 1186 lymph nodes were diagnosed as negative for metastases by routine histopathological analysis and were further examined for the presence of isolated tumor cells with the monoclonal anti-epithelial antibody AE1/AE3.
Twenty-two tumors (42.3%) showed a major histopathologic response whereas in 30 tumors (57.7%) only a minor response was present. Of 32 patients with a pN0 category, major response was present in 19 (59.4%) tumors, whereas 13 (40.6%) tumors showed minor response. Nine (69%) out of 13 patients with minor response had AE1/AE3-positive cells in their lymph nodes, whereas only four (21%) out of 19 pN0-patients with major response showed nodal micrometastasis (P = 0.013, chi(2)-test).
If tumors show a major histomorphologic response following neoadjuvant chemoradiation, the presence of nodal micrometastasis is significantly reduced compared to those with minor response.
食管癌的新辅助治疗方式旨在改善局部肿瘤控制,以及减少局部晚期食管癌患者的淋巴结转移和远处转移。其对淋巴结微转移的影响尚未得到评估。
本研究纳入52例局限性(cT2 - 4,Nx,M0)食管癌患者(21例腺癌,31例鳞状细胞癌),这些患者接受新辅助放化疗(36Gy,5 - 氟尿嘧啶,顺铂),随后行经胸整块食管切除术及两野淋巴结清扫术。组织形态学消退程度如最近报道的那样分为主要反应(<10%)和次要反应(>10%存活残留肿瘤细胞)。通过常规组织病理学分析,共有1186个淋巴结被诊断为无转移,并进一步用单克隆抗上皮抗体AE1/AE3检测是否存在孤立肿瘤细胞。
22例肿瘤(42.3%)显示主要组织病理学反应,而30例肿瘤(57.7%)仅显示次要反应。在32例pN0分期的患者中,19例(59.4%)肿瘤有主要反应,而13例(40.6%)肿瘤显示次要反应。13例有次要反应的患者中有9例(69%)其淋巴结中有AE1/AE3阳性细胞,而19例有主要反应的pN0患者中只有4例(21%)显示有淋巴结微转移(P = 0.013,卡方检验)。
新辅助放化疗后若肿瘤显示主要组织形态学反应,与次要反应的肿瘤相比,淋巴结微转移的发生率显著降低。